The objective of the present study was to investigate the cholesterol-reducing effect of medium-chain fatty acids (MCFAs) completed by elevated excretion of fecal neutral steroids and/or bile acids. Blood and liver lipid profiles, fecal neutral steroids, bile acids, and mRNA and protein expression of the genes relevant to cholesterol homeostasis were measured and analyzed in C57BL/6J mice fed a cholesterol-rich diet with 2% caprylic acid or capric acid for 12 weeks. Blood total cholesterol and low-density lipoprotein cholesterol (LDL-c) levels were reduced significantly as compared to diet with palmitic acid or stearic acid. Caprylic acid promoted the excretion of fecal neutral steroids, especially cholesterol. The excretion of fecal bile acids, mainly in the form of cholic acid was enhanced and accompanied by elevated expression of mRNA and the protein of hepatic cholesterol 7-hydroxylase (CYP7A1). These results indicate that MCFAs can reduce blood cholesterol by promoting the excretion of fecal cholesterol and cholic acid.
Currently, cardiovascular disease (CVD) remains the major cause of human death worldwide. 1) High blood cholesterol is thought to be a crucial risk factor for CVD. Lifestyle interventions are the cornerstone for decreasing the risk of CVD. The major lifestyle modifications recommended are healthy diet, weight control, regular physical activity, quitting smoking, and moderate alcohol consumption.
2) As one of the key components of a healthy diet to prevent CVD, reducing the intake of dietary cholesterol and saturated fatty acids (SFAs) is recommended extensively, 3, 4) because over the past 50 years accumulating evidence has suggested that most SFAs increase blood total cholesterol (TC) and low density lipoprotein cholesterol (LDL-c). 5, 6) Evidence of increasing blood cholesterol and risk of CVD due to dietary intake of SFAs was found in the Seven Countries Study 7) and the relationship was demonstrated in short 8) and long-term feeding trials. 9) Not all SFAs have similar cholesterol-raising effects, and different SFAs have its diverse biological functions. 10) Medium-chain fatty acids (MCFAs) possess 8-10 carbons and are saturated. They were found not to increase the risk of coronary heart disease in the Nurses' Health Study. [11] [12] [13] More and more reports indicate that the health effects of SFAs vary depending on carbon chain length, and for this reason, the association between different SFAs and the risk of CVD should be investigated intensively. 14) Some investigations in the past a few years have reported that intake of medium-chain triglyceride (MCT) and of MCFAs caused reductions in TC and LDL-c but no change in high density lipoprotein cholesterol (HDL-c). [15] [16] [17] [18] Our previous studies suggested that dietary oil containing MCFAs can reduce serum TC and LDL-c and increase HDL-c in hypertriglyceridemic subjects as compared to oil containing long-chain fatty acids (LCFAs). [19] [20] [21] Further studies have confirmed the reduction of blood TC and LDL-c by MCFAs in C57BL/6J mice, 22, 23) but the exact mechanism responsible for the reduction of cholesterol by MCFAs has been not investigated intensively. Here, based on our previous reports, we hypothesize that MCFAs reduced blood cholesterol by promoting the excretion of fecal neutral steroids and/or bile acids in C57BL/6J mice fed a cholesterol-rich diet.
Materials and Methods
Animals. Two hundred male C57BL/6J mice (4 weeks old) were obtained from the Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (license no. SCXK: JING2009-0007), and were housed in a room at 22 AE 1 C at 40% to 60% humidity under a 12-h light/dark cycle (lights on from 8:00 to 20:00). The experiments were conducted in accordance with the Guidelines of the Animal Care and Use Committee of the Chinese PLA General Hospital.
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Abbreviations: AN, acetonitrile; BA, bile acid; CA, cholic acid; CDCA, chenodeoxycholic acid; CVD, cardiovascular disease; CYP7A1, cholesterol 7-hydroxylase; DCA, deoxycholic acid; EHC, enterohepatic circulation; GCA, glycocholic acid; GCBAs, glycine-conjugated bile acids; GCDCA, glycochenodeoxycholic acid; GDCA, glycodeoxycholic acid; HDL-c, high-density lipoprotein cholesterol; HMG-CR, 3-hydroxy-3-methylglutaryl CoA reductase; IS, internal standard; LCA, lithocholic acid; LCFA, long-chain fatty acid; LDL-c, low-density lipoprotein cholesterol; MCFA, medium-chain fatty acid; MCT, medium-chain triglyceride; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid; TC, total cholesterol; TCA, taurocholic acid; TCBAs, taurine-conjugated bile acids; TCDCA, taurochenodeoxycholic acid; TDCA, taurodeoxycholic acid; TG, triacylglycerol; TLCA, taurolithocholic acid; UCBAs, unconjugated bile acids Diets. A commercial standard diet (purchased from the Academy of Military Medical Sciences and based on the AIN-96G diet) was used as basal diet. The mice had access to the basal diet and water ad libitum for 1 week to stabilize their metabolic condition. Fifteen mice were randomly selected and fed the basal diet as normal control. The other mice were fed a cholesterol-rich (CR) diet (Table 1) modified from AIN-96G. After 4 weeks, only those whose levels of serum total cholesterol (TC) were over 40% more than those of the normal control mice were chosen for the experiment. Mice with high blood cholesterol were randomly assigned to six groups (10 mice in each group) according to their fasting blood TC levels (blood samples were collected from the mandibular venous plexus), and were fed six different experimental diets containing 2% caprylic acid (C8:0), 2% capric acid (C10:0), 2% palmitic acid (C16:0), 2% stearic acid (C18:0), 2% oleic acid (C18:1), and 2% -linolenic acid (C18:3) respectively for 12 weeks (Tables 1 and 2 ). The fatty acids used were purchased from Sigma-Aldrich (Bellefonte, PA).
Feces, blood and liver tissue sampling. In view of the limited metabolic cages available, five mice were chosen randomly from each group to record diet intake and sampe feces output. Daily diet intake and the feces of each mouse were recorded using the metabolic cage for 3 d at the start and the end of the study. The feces were lyophilized, weighed, pulverised, and stored at À80
C until further analysis. At the end of the study, all mice were deprived of food, but not water, for overnight fasting (at least 12 h). In the morning after the fast, the mice were anesthetized by intramuscular injection of xylazine hydrochloride at a dose of 10 mg/kg, and blood samples were collected from the aorta ventralis. The blood samples were centrifuged at 2;000 g for 10 min, and sera were collected and stored at À80 C for later analysis. Livers were excised, rinsed with icy saline, and weighed, and immediately frozen in liquid nitrogen and stored at À80 C until analysis.
Measurement of blood and liver tissue lipid profiles. The levels of TC and triglyceride (TG) in the blood and liver were determined by enzymatic colorimetric methods with commercial kits (Wako Pure Chemical Industries, Osaka, Japan, nos. 290-63701 and 294-65801), and high-density lipoprotein cholesterol (HDL-c) and low-density lipoprotein cholesterol (LDL-c) were measured by sediment methods with a commercial kit (Abcam, Cambridge, UK, no. ab65390). Serum total bile acid was measured by commercial kits (Blue Gene, Shanghai, China, no. E03T0504). Liver phospholipid (PL) was measured by commercial kit (Wako Pure Chemical Industries, Osaka, Japan, no. 296-63801).
Real-time RT-PCR analysis. mRNA expression of 3-hydroxy-3-methylglutaryl CoA reductase (HMG-CR) and cholesterol 7-hydroxylase (CYP7A1) in the liver was measured by quantitative real-time RT-PCR. Total RNAs were isolated from the liver with Trizol reagent (Omega Bio-Tek, Norcross, GA, no. R6812). cDNAs were synthesized from 3 mg of RNA by M-MLV reverse transcriptase (Invitrogen, Carlsbad, CA). After cDNA synthesis, quantitative real-time PCR was performed in 25 mL of PlexorTM by the One-Step qRT-PCR System (Promega Corporation, Madsion, WI, no. A4021), using a fluorometric thermal cycler (Bio-Rad CFX96TM, Bio-Rad Laboratories, Hercules, CA). The following experimental conditions were imposed for all target gene expression, including the generation of standard curves. Each reaction mixture was incubated for initial denaturation at 95 C for 5 min, followed by 39 cycles of 95 C for 15 s, 60 C for 20 s, and 68 C for 20 s. Primers were designed with Primer Express 3.0 software, and all primers were synthesized by a commercial company (Songon Biotechnology, Shanghai, China). The sequences of the primers used were as follows: CYP7A1 NM 007824.2: forward (
, ATGTCACGCACGATTTCCC. -Actin was used as control to normalize gene expression. The ÁCt method was used to determine relative quantification. The ÁCt value for each sample was determined by calculating the difference between the Ct value of the target gene and that of the -actin reference gene. The normalized target gene expression level in the sample was calculated by the formula 2 ÀÁÁCt ð2 ÁCtðactinÞÀÁCtðtarget geneÞ ).
Western blotting analysis. Ten mg of frozen liver tissue was added to 200 mL of a protein lysate solution, and this was homogenized with a glass grinder on ice. The homogenate was centrifuged at 16;000 g for 15 min at 4 C to create a supernatant for subsequent measurement. The protein in the supernatant was measured with a BCA kit (Pierce Chemical Company, USA, no. 23225). For electrophoresis, 50 mg of total protein was mixed with a 5-fold loading buffer, and the mixture was boiled for 5 min and then immediately cooled in ice. The sample was size-fractionated on 10% SDS-PAGE gel and then electrophoretically transferred to a nitrocellulose membrane using 0.48 mol/L of Tris base, 0.39 mol/L of glycine, and 20% methanol (pH 8.0) as transfer buffer. The membrane was then incubated overnight at 4 C with Tris buffer and a 0.5% blocking solution containing primary antibody anti--actin (5,000-fold diluted, Abcam, Cambridge, UK), anti-CYP7A1 (200-fold diluted, Santa Cruz Biotechnology, Santa Cruz, CA) or anti-HMG-CR (200-fold diluted, Biovision Incorporated, Milpitas, CA). The diluted HRP membrane labeled with closure of the secondary antibody (Jackson ImmunoResearch Laboratories, Baltimore, PA) at a dilution ratio of 1:10,000, and the secondary antibody-diluted membrane were incubated for 2 h. They were processed further with a chemiluminescence Western blotting kit (Sun Biomedical Technology, Beijing, China) following the manufacturer's protocol. Signal intensity was measured by densitometry with software Image-Pro Plus 6.0.
Fecal neutral steroid analysis. Feces were lyophilized after hairs and food attached to the feces were removed. Homogenized fecal matter (100 mg), with 5-cholestane (Sigma-Aldrich, Bellefonte, PA) as internal standard (IS), was extracted with methanol-chloroform (2:1, v/v), and the sample was saponified in 2 mL of methanolic KOH for 2 h at 50 C. After cooling to ambient temperature and adding 2 mL of deionized water, the lipids were extracted into 5 mL of hexane. The hexane was removed under N 2 gas, and the samples were derivatized before gas chromatography (GC) by the addition of 100 mL of pyridine (Sigma-Aldrich), followed by 50 mL of Sylon BTZ (Supelco, Bellefonte, PA). The injection volume of all samples was 5 mL. A GC-2010 series GC system (Shimadzu, kyoto, Japan) directly connected to a GCMS-QP2010 plus series mass selective detector (Shimadzu) was used. An Rtx-1 (0.25 mm, 0:25 mm Â 30 m) column (Restek, Bellefonte, PA) was used for the analysis. Helium was used as the carrier gas at a constant flow rate of 0.64 mL/min. The inlet temperature was 280 C and the split ratio was À1.0. The oven temperature was controlled as follows: the initial temperature was 190 C, raised to 286 C at a rate of 3 C per min and maintained for 3 min. The ion source and detector temperatures were 230 and 280 C respectively. The electron impact (EI) ionization mode was chosen, and all of the ions were monitored in scan mode. Verification of compounds of interest was accomplished by comparison with standard substances. All quantitative calculations were based on the peak area ratios relative to the IS. Cholesterol, cholestanol and coprostanol were purchased from Sigma-Aldrich, and were used as standard substances.
Fecal bile acid analysis. Lyophilized feces (50 mg) with 100 mg over chloramphenicol were extracted with 5 mL of ethanol at 80 C for 10 min, and then the supernatants were collected. The ethanol was removed under N 2 gas, and then the residue was dissolved in methanol and passed through a 0.45-mm filter (C3 LH, Millipore, Bedford, MA). The filtrates were diluted 100-fold with methanol. The injection volume of all samples was 5 mL. A Shimadzu LC-20AD high performance liquid chromatography system (Shimadzu) coupled to an Applied Biosystem 3200 Q TRAP mass spectrometer with an electrospray ionization (ESI) source (Applied Biosystems, Carlsbad, CA) was used throughout. The HPLC and MS systems were controlled by Analyst 1.4.2 software. All chromatographic separations were performed with a Venusil AQ C18 column (2.5 mm, 50 mm Â 2:1 mm) from Agela. The mobile phase consisted of 95% acetonitrile (AN) (mobile phase A) and 2.5 mM ammonium acetate with 5% AN and 0.05% methanoic acid (mobile phase B) gradient systems at a total flow rate of 0.4 mL/min. All BAs were detected in negative ionization mode with the following mass spectrometer source settings: ion spray voltage, À4,500 V; source temperature, 500 C; source gas 1 ¼ 50 psi, source gas 2 ¼ 50 psi; declustering potential (DP), À66 to À88; collision energy (CE), À30 to À110. The multiple reaction monitored (MRM) transition was used for each analyte and IS. The parent and productions of the analytes and IS used for MS analysis followed a similar study. 24) Cholic acid (CA), deoxycholic acid (DCA), chenodeoxycholic acid (CDCA), ursodeoxycholic acid (UDCA), lithocholic acid (LCA), taurocholic acid (TCA), taurodeoxycholic acid (TDCA), taurochenodeoxycholic acid (TCDCA), taurolithocholic acid (TLCA), glycocholic acid (GCA), glycodeoxycholic acid (GDCA), and glycochenodeoxycholic acid (GCDCA), purchased from Sigma-Aldrich, were used as standard substances. The chloramphenicol used as internal standard was purchased from Sigma-Aldrich.
Statistical analysis. All data were expressed as the means AE SD. Statistical significance of differences among the six groups was subjected to one-way analysis of variance. When homogeneity of variance was satisfied the LSD method was used in pairwise comparison, otherwise Tamhane's T2 method was employed. The statistical significance of differences between the start and the end of the experiment in a given group was subjected to paired t-test. p < 0:05 was taken to be statistically significant.
Results

Effects of MCFAs on body weight and lipid profiles in the blood and liver
ANOVA analysis indicated that there were significant differences in body weights among the experimental groups at the end of the experiment. The body weights in the C8:0, C10:0 and C18:1 groups were significantly lower than those in the C16:0 or the C18:0 group. The levels of blood TC and LDL-c became much lower in the C8:0, C10:0, and C18:3 groups than in the C16:0 group. The levels of blood HDL-c were not different among the six groups, but the ratios of HDL-c/LDL-c in the C8:0, C10:0, and C18:3 groups were higher than those in the C16:0 or the C18:0 group. The levels of blood TG decreased more in the C8:0, C10:0, C18:1, and C18:3 groups than in the C16:0 group. The lipid profiles of the liver showed no significant difference among the six groups (Table 3) .
Effects of MCFAs on dietary cholesterol intake, feces output, and fecal neutral steroid excretion
There were no significant differences in dietary cholesterol intake or dry feces output among the six groups during 3 d of metabolic cage observation at the end of the experiment (Table 4 ). As shown in Table 4 , cholesterol was the major component of the fecal steroids in all groups. Much more cholesterol and total neutral steroids were excreted in those fed C8:0 than in the mice fed C16:0 or C18:0. Cholestanol excretion was a little higher in the C8:0 group than in the C16:0 group (Table 4) .
Effects of MCFAs on fecal BAs excretion
Based on our results (Table 5) , CA accounted for up to 77-87% of total BAs in the groups, and was the major component of fecal BAs. No differences in CA content were found in the mice feces at the start of the experiment among the groups, but the C8:0, C10:0, and C18:3 enhanced CA excretion more than C18:0 at the end of 12 weeks in the experiment. Furthermore, CA excretion in the C8:0 group obviously increased at the end as compared to the start of the experiment (Fig. 1) .
After 12 weeks, total UCBA excretion was significantly higher in the C8:0 and the C10:0 group than in the C16:0 or the C18:0 group. Excretion of UDCA and LCA in the C8:0 group was markedly higher than in the C16:0 or the C18:0 group, and the excretion of UDCA in the C10:0 and the C18:3 group was noticeably higher than in the C18:0 group. Similar results for CA and UDCA were also observed between the C18:3 and the C18:0 group.
Taurine-conjugated bile acid (TCBA) excretion in the C8:0, C10:0, and C18:1 groups were significantly higher than in the C18:0 group, and total TCBA excretion was also significantly higher in the C10:0 group than in the C16:0 group. Excretion of TDCA and TCDCA in the C8:0, C10:0, and C18:3 groups were higher than in the C16:0 or the C18:0 group.
There were no significant difference in the excretion of GCA and GDCA among the groups, but excretion of total glycine-conjugated bile acid (GCBA) and GCDCA was significantly higher in the C18:1 group than in the C16:0 group.
Effects of MCFAs on mRNA, and protein expression of CYP7A1 and HMG-CR in the livers
mRNA expression of CYP7A1 in the C8:0 and the C10:0 group was significantly higher than in the C16:0 or the C18:0 group ( Fig. 2A) , but mRNA expression of HMG-CR was not different among the groups (Fig. 2B) . Western-blotting analysis indicated that protein expression of CYP7A1 in the C8:0 and the C10:0 group was much higher than in the C16:0 or the C18:0 group (Fig. 3A, B) , but no significant differences were found in HMG-CR among the groups (Fig. 3A, C) .
Discussion
It is generally accepted that SFAs increase blood TC and LDL-c. 5, 6) LCFAs are packed into chylomicrons, bypass the liver via the lymphatic system, and are delivered to extrahepatic tissues. Structurally, MCFAs are saturated fatty acids. Unlike LCFAs, MCFAs are directly transported to the liver via hepatic portal circulation and are readily oxidized to ketones. 25) Although recent studies indicate that separate SFAs have diverse cholesterol-raising effects, most studies 24:2 AE 4:7 2 9 :9 AE 11:9 3 1 :8 AE 6:9 3 1 :3 AE 10:6 have focused on saturated long-chain fatty acids such as palmitic acid and stearic acid instead of MCFAs. A few results have shown reductions in TC and LDL-c by MCT or MCFAs. [15] [16] [17] [18] Our previous studies also showed similar results in humans [19] [20] [21] and mice 22, 23) due to intake of MCT. To the best of our knowledge, few studies to date have examined the effect of intake of C8:0 or C10:0 on cholesterol metabolism in humans or animals. In the present study, we observed the effects of six different fatty acids on blood TC and LDL-c, and fecal neutral steroid and BA excretion by feeding a cholesterol-rich diet with 2% MCFA (C8:0 or C10:0), LFCA (C16:0 or C18:0), 2%MUFA (C18:1) or PUFA (C18:3) to C57BL/6J mice. Our results indicated that intake of MCFAs is more effective in lowering body weight, blood TG, TC, and LDL-c levels than intake of saturated LCFAs is. These results indicate that MCFAs improve blood lipid profiles, including cholesterol, much better than saturated LCFAs do.
Cholesterol homeostasis in mammals is maintained through integrated regulation of three major metabolic pathways in the liver. The pathways supplying cholesterol to the cells include an endogenous biosynthetic pathway and an exogenous pathway, while a third pathway is the major disposal rout for cholesterol in mammals by transforming it into bile acids, which are ultimately excreted from the body. 26, 27) Cytochrome P450s play crucial roles in the catabolism of cholesterol to bile acids in two major pathways: the classic and the alternative. The classic pathway leads to two primary BAs, CA and CDCA. Synthesis begins with the formation of CYP7A1, the rate-limiting enzyme of the classic pathway. In the alternative pathway, the first step involves the oxidation of cholesterol to 27-hydroxycholesterol by CYP27A1, and leads mainly to the formation of CDCA.
27) The bile acid pool in mice consists mostly of hydrophilic BAs, muricholic acids, and CA. In the intestine, glycine-and taurine-conjugated CA and CDCA are deconjugated, and CYP7A1 activity in bacteria flora removes a 7-hydroxy group to form secondary bile acids DCA and LCA respectively. CA, CDCA, and DCA are reabsorbed in the intestine and transported back to the liver, inhibiting BA synthesis. Most of the LCA is excreted in the feces. 28) For the first time, we found that mice fed a diet with MCFAs upregulated BA and cholesterol excretion, specifically CA, but not CDCA synthesis and excretion in comparison to MUFAs and LCFAs. Quantitative realtime PCR and Western-blotting analysis indicated that MCFAs upregulated both the transcriptional and the post-transcriptional levels of CYP7A1 as compared to LCFAs in the mouse liver. This result indicates that MCFAs stimulate fecal CA excretion, probably associated with the classic pathway of the catabolism of cholesterol to BAs, through an increase in CYP7A1. No differences were found either in the transcriptional or in the post-transcriptional level of HMG-CR in the mouse liver. In this regard, MCFAs upregulate cholesterol elimination but not cholesterol biosynthesis, a possible mechanism whereby MCFAs reduce serum TC and LDL-c.
Enterohepatic circulation (EHC) of BAs, the end products of cholesterol metabolism, is a highly efficient process that is vitally important for the maintenance of bile flow and hepatic secretary function. In the EHC, each bile salt molecule is reused about 10 times, only 1-20% of secreted bile beings lost in the feces. 29) We identified significant reductions in serum TC, increases in BAs synthesis and excretion, and no change in lipid profile in the liver by MCFAs, but we did not find serum BA elevation in the MCFA group as compared with the LCFA group (Table 3) . This suggests that absorption of BAs is not increased, and that increased fecal BA excretion controls the blood serum BA concentration. Similar results have been reported in other studies of PUFAs. 30, 31) Although the best known role of BAs is their participation in the digestion and absorption of fat, they also play important roles in their own hepatic synthesis and hepatic and intestinal transport. 32) It has been reported that bile acids reduce CYP7A1 mRNA stability via bile acid response elements located in the 3 0 -untranslated region. 33, 34) In mice, CA functions as a signaling molecule that downregulates the expression of CYP7A1. 35) Whether increased CA excretion due to MCFAs reduces the CA concentration in the BA pool or indirectly upregulates the transcription and the posttranscription level of CYP7A1 in liver needs further clarification.
In summary, the present study indicated that MCFAs, especially caprylic acid, improved cholesterol metabolism in C57BL/6J mice fed a cholesterol-rich diet. This effect was mediated by enhancement of the excretion of fecal cholesterol and cholic acid through upregulated CYP7A1 in the liver. 
